We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Treatment With Duloxetine for OCD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00399022
Recruitment Status : Withdrawn (Funding was not recieved)
First Posted : November 14, 2006
Last Update Posted : January 31, 2008
Information provided by:
Sheba Medical Center

Brief Summary:
Testing the efficacy of the SNRI medication Duloxetine for treating OCD patients who did not respond to SSRI

Condition or disease Intervention/treatment
OCD Drug: Duloxetine

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • OCD as main diagnosis according to DSM-IV
  • Age 18 to 65
  • Men and women
  • YBOCS score is 18 or more, or 12 or more in case of only obsessions

Exclusion Criteria:

  • Patients treated with Duloxetine, currently or in the past
  • Patients having comorbid schizophrenia or psychotic disorder or bipolar disorder Patients with substance abuse disorder in the last 6 months Patients who were suicidal or did serious suicide attempt in the last year Pregnant or lactating women, or woman of childbearing potential, which is not using adequate contraception Patients with neurologic disturbance or disorder Patients with serious or imbalanced medical condition Patients with allergic response to SSRI or duloxetine Patients who started new treatment (CBT or pharmacology) in less than 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00399022

Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Joseph Zohar, MD Chaim Sheba Medical Center

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00399022     History of Changes
Other Study ID Numbers: SHEBA-06-4360-JZ-CTIL
First Posted: November 14, 2006    Key Record Dates
Last Update Posted: January 31, 2008
Last Verified: January 2008

Additional relevant MeSH terms:
Duloxetine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs
Dopamine Agents